score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q449*	0.2696	204.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0.0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0	0.0	0.0	0.0	ARID1A p.Q449* (Nonsense)		KIRP-2Z-A9J5	KIRP-2Z-A9J5-TP	KIRP-2Z-A9J5-NB
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 3	version 2	0.418						Investigate Actionability	Platinum	Platinum-based chemotherapy	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683													0				COSMIC Signature (version 2) 3 (42%)		KIRP-2Z-A9J5		
Biologically Relevant				Copy Number	TSC2	Amplification				0.0	0.0																					0				TSC2 Amplification		KIRP-2Z-A9J5	TCGA-2Z-A9J5-01	
Biologically Relevant				Copy Number	PALB2	Amplification				0.0	0.0																					0				PALB2 Amplification		KIRP-2Z-A9J5	TCGA-2Z-A9J5-01	
Biologically Relevant				Microsatellite Stability	Supporting variants		DOCK3 p.N1083fs (Frameshift), PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: DOCK3 p.N1083fs (Frameshift), PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)		KIRP-2Z-A9J5		
